Corner Therapeutics

Exciting news – we are thrilled that our President and Scientific Co-founder?Jonathan Kagan has been named on?Clarivate's list of Highly Cited Researchers! This recognition highlights Jon's significant contributions to advancing our understanding of the immune system and its role in combating disease, which is the engine room driving Corner's mission to unlock lifelong protection. Congratulations, Jon! Your work continues to inspire us and push the boundaries of science. #CornerTX #BiotechResearch https://lnkd.in/e-HaKduj

At Corner Therapeutics, we always look for ways to be on the cutting edge of research and technology to better serve our future patients! ? Last week we held a?lunch and learn?about AI in biotech led by Nicholas Seaver, Nicolina Lamberti, Stephan Matissek, and Dania Zhivaki! ? It was a great opportunity to discuss the state of AI and how it is being used in the greater biotech landscape, and how Corner can use AI tools to make us more efficient in the future. ? All 4 employees gave thought-provoking presentations on their views of AI and how each of them have used AI in their day to day processes. Their presentations led to dynamic conversations about the future opportunities of AI in the biotech space and encouraged other employees to look into how they could use AI. #CornerTX #LearningAndDevelopment #CorporateCulture

This year, Corner Therapeutics partnered with RACE Cancer Foundation for its "Boston Summer Series 5ks" as an official sponsor! With 100% of the race's proceeds fueling cancer research and education, this partnership both highlights our shared values and our collective drive to fight cancer and promote health and wellness. Thank you to Emily Gosselin, Anastasia Nikiforov, Cullen Clougherty, Catherine A. Gormley, Nicolina Lamberti and RACE Cancer Foundation for their dedication. We look forward to continuing this meaningful work towards a cancer-free future. #CureforCancer #CornerTX #CancerResearch

One of Corner’s goals is to foster an environment of shared stories, experiences, and knowledge that unites all members of our team. Initiatives like Lunch and Learns with experts, development training sessions, and a mentorship program build a culture of continuous learning. We do this because we believe that an engaged, well-equipped, and interconnected team is the bedrock of our success. Share our mission and values? We're currently hiring for a range of scientific positions – learn more at?https://lnkd.in/ehPbv8zr #CornerTX #LearningAndDevelopment #CorporateCulture #Hiring

Our team was grateful to be among some of the most brilliant minds in the field at the 17th International Symposium on Dendritic Cells in Barcelona last week. Our scientists Kelsey Finn and Stephan Matissek were pleased to share their latest research on?hyperactivating dendritic cells –?the apex regulators of the immune system. Conferences like #DC2024 are crucial to furthering our mission?to revolutionize cancer treatment and infectious disease.?See you again next year! #CornerTX #DC2024Barcelona #BiotechResearch

Our Co-founder and President Jonathan Kagan gave the keynote address at BioNTech SE's North American Retreat in Cambridge earlier this month! ? Jon shared the unique technology from both his lab and Corner designed to unlock the potential of cancer vaccines through robust and durable T cell responses (which also, by the way, promises to significantly improve infectious disease vaccines!)? ? Thank you BioNTech for inviting Jon to share the latest in frontier-pushing immunity research. ? #CornerTX #CancerResearch #BioNTech?

Next week at the 17th International Symposium on Dendritic Cells in Barcelona, our scientists Kelsey Finn and Stephan Matissek will share their latest research into supercharging dendritic cells – the apex regulators of the immune system. Kelsey will present a poster on developing adjuvants that hyperactivate dendritic cells to stimulate a robust T Cell response to diverse viral antigens. Stephan will share research on stimulating robust T Cell responses using a vaccine adjuvant that activates NLRP3 inflammasomes in living dendritic cells. Attending the symposium? Get in touch to meet our scientists and learn more about Corner’s mission to generate immunity for life. #CornerTX #DC2024Barcelona #BiotechResearch #DendriticCells

We're #hiring a new Scientist I, Preclinical in Watertown, Massachusetts. Apply today or share this post with your network.

Our Co-founder and President Jonathan Kagan recently chaired a panel on the transformative potential of therapeutic cancer vaccines at the Fierce Biotech Summit in Boston!?? ? Cancer vaccines have long been the holy grail of medicine. We believe our research at Corner is the linchpin to revolutionizing cancer treatment and infectious disease prevention.? ? Thank you to Jeff Allen, President & CEO at Friends of Cancer Research, Ildiko Csiki, M.D., Ph.D., Chief Medical Officer at Geneos Therapeutics, and Scot Ebbinghaus, Vice President and Therapeutic Area Head for Late Stage Oncology Clinical Development at Merck, who joined Jon for the discussion.? ? #CornerTX #CancerResearch #FierceBiotech?

Kelsey Finn is #hiring a #Scientist on the pre-clinical team at Corner Therapeutics! The ideal candidate will help design and lead pre-clinical in vivo pharmacological studies to evaluate Corner’s novel catalytic adjuvant platform as part of proof-of-concept studies and partnership-enabling studies. To learn more about this role follow the link below.